Alpha Tau Medical Ltd.
DRTSHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the. The company carries a $1.22B market cap, placing it firmly in the small-cap category. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
Market Cap
$1.22B
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
-26.32
EPS (TTM)
$-0.76
EPS (Fwd)
$-0.51
ROE
-90.5%
ROA
-30.5%
Cash
$76.4M
Total Debt
$14.3M
Free CF
—
52W Change
345.7%
Annual Financials
Cash vs Debt
With $76.4M in cash and $14.3M in debt, DRTS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. ROE of -90.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, DRTS has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Alpha Tau Medical Ltd.'s trajectory.